Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + rilvegostomig + carboplatin
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination therapy of three agents: - **Trastuzumab deruxtecan (T-DXd, DS-8201a, Enhertu)**: an antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor cytotoxic payload. It delivers chemotherapy directly to HER2-overexpressing tumor cells, causing DNA damage and apoptosis. - **Rilvegostomig (AZD2936)**: a novel bispecific monoclonal antibody targeting both PD-1 and TIGIT immune checkpoints. It is designed to enhance antitumor immune response by dual blockade, increasing T-cell mediated tumor cell killing. - **Carboplatin**: a platinum-based chemotherapy agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. This combination is being studied as a first-line therapy for HER2-expressing, mismatch repair proficient, advanced or recurrent endometrial cancer in Phase 3 clinical trials. It is administered intravenously.
- Other names
- trastuzumab deruxtecan + rilvegostomig + carboplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA
Beyond the preview
Go deeper on trastuzumab deruxtecan + rilvegostomig + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + rilvegostomig + carboplatin.